Form 4: Veracyte Director Karin Eastham Sells Shares Under 10b5-1 Plan

Karin Eastham, a director at Veracyte, Inc., sold 3,870 shares of common stock at a price of $20.59 on June 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 11, 2024, Karin Eastham, a director of Veracyte, Inc. (VCYT), sold 3,870 shares of the company's common stock.
• The sale was executed at a price of $20.59 per share.
• Following the transaction, Eastham directly owns 29,255 shares of Veracyte.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 8, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it simply reports the sale of shares by a company director under a pre-existing plan.

Industry Context

Insider sales are a common occurrence, and sales under 10b5-1 plans are generally viewed as less impactful since they are pre-scheduled and not necessarily indicative of the insider's current view of the company's prospects.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates